# Nuvectis Pharma Inc. (NVCT) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $19.34, market value $631 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Nuvectis Pharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 56.9×**. The shares trade at 56.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -143.6%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -18.9%**. Earnings per share fell 18.9%.

## Financial health
- **Current ratio: 2.38** (quick 2.38). Current assets cover the next year's liabilities 2.38 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Nuvectis Pharma Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Nuvectis Pharma Inc.; the consensus is strong_buy, with an average price target of $35.40 (+83% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 204.1%** (YTD 156.2%, 3-mo -3.8%). The shares are up 204.1% over twelve months including dividends.
- **From 52-week high: -33.9%** (248.5% above the low). Trading 34% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 0.89** (volatility 86%). Beta of 0.89 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NVCT · Page: https://foliofundamentals.com/stocks/nvct

Not investment advice.